



## Company Announcement

### **Nykode Therapeutics - approval and publication of prospectus and admission to trading on the Oslo Stock Exchange's main list**

Oslo, Norway, June 15, 2022 – Nykode Therapeutics ASA (Euronext Growth Oslo: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced further updates regarding its stock exchange uplisting process.

Reference is made to the announcement by Oslo Stock Exchange on June 13, 2022, regarding the approval of the transfer of listing of the shares in Nykode Therapeutics ASA from trading on Euronext Growth Oslo to the Oslo Stock Exchange's main list.

The first day of trading of the Company's shares on the Oslo Stock Exchange's main list is expected to be on or about June 16, 2022. Consequently, the last day of trading of the Company's shares on Euronext Growth Oslo is expected to be today, June 15, 2022.

The Company has prepared a prospectus in connection with the listing of its shares on the Oslo Stock Exchange's main list. The prospectus was approved by the Norwegian Financial Supervisory Authority today, June 15, 2022, and will be available at the Company's web page from June 16, 2022 at 8.00 a.m. CET at [www.nykode.com/investors/financial-reports-and-presentations](http://www.nykode.com/investors/financial-reports-and-presentations).

#### **About Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase II trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group, and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer.



Additionally, Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.

The Company's partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on Euronext Growth Oslo, a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is NYKD. Further information about Nykode Therapeutics may be found at [www.nykode.com](http://www.nykode.com).

**Contact for Nykode Therapeutics ASA:**

CFO Harald Gurvin  
Nykode Therapeutics ASA  
[IR@nykode.com](mailto:IR@nykode.com)

**Nykode Therapeutics ASA**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway

**Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.